European equities traded in the US as American depositary receipts were tracking sharply lower late Tuesday morning, declining 1.71% to 1,313.74 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which rose 4.4% and 1.1% respectively. They were followed by accommodations booking platform trivago (TRVG), which rose 0.6%.
The decliners from continental Europe were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 1.7% and 3.7% respectively. They were followed by oil and gas company TotalEnergies (TTE) and pharmaceutical company Novo Nordisk (NVO), which dropped 3.2% and 2.6% respectively.
From the UK and Ireland, the gainers were led by software firm Endava (DAVA) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 7.4% and 2.5% respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and TC Biopharm (TCBP), which increased 2% and 1.9% respectively.
The decliners from the UK and Ireland were led by telecommunications operator Vodafone Group (VOD) and biopharmaceutical company Mereo BioPharma Group (MREO), which lost 7.9% and 5.1% respectively. They were followed by insurance firm Prudential (PUK) and pharmaceutical Silence Therapeutics (SLN), which dropped 5% and 4% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。